bioRxiv Science⌕ Search

Biology subjects

Herrera-Montavez, C.

Publications and source records attributed to Herrera-Montavez, C..

2 recordsLinked to original sources

MEK1/2-Targeting PROTACs Promote the Collateral Degradation of CRAF in KRAS Mutant Cells

Withdrawal StatementFollowing extensive additional studies, we discovered new findings that suggest that the degradation of CRAF by MS934 is not via collateral degradation through proximity to MEK1/2 but rather via a cell intrinsic mechanism that occurs post MEK1/2 degradation in KRAS mutant cells. We have performed extensive time course experiments exploring MS934-mediated degradation of CRAF, as well as additional MEK1/2 knockdown studies in several cell line models. Data from these studies showed that MEK1/2 proteins are degraded by MS934 several hours before CRAF protein and that genetic depletion of both MEK1 and MEK2 reduces CRAF protein levels equivalent to that observed with MS934. Together, these new findings suggest that CRAF degradation is not due to collateral proximity degradation by MS934 but rather due to a cell intrinsic mechanism post MEK1/2 protein depletion.

cancer biology↗

MDR1 Drug Efflux Pump Promotes Intrinsic and Acquired Resistance to PROTACs in Cancer Cells

PROTACs (Proteolysis-Targeting Chimeras) represent a promising new class of drugs that selectively degrade proteins of interest from cells. PROTACs targeting oncogenes are avidly being explored for cancer therapies, with several currently in clinical trials. Drug resistance represents a significant challenge in cancer therapies, and the mechanism by which cancer cells acquire resistance to PROTACs remains poorly understood. Using proteomics, we discovered acquired and intrinsic resistance to PROTACs in cancer cells can be mediated by upregulation of the drug efflux pump MDR1. PROTAC-resistant cells could be re-sensitized to PROTACs through co-administering MDR1 inhibitors. Notably, co-treatment of MDR1-overexpressing colorectal cancer cells with MEK1/2 or KRASG12C degraders and the dual ErbB receptor/MDR1 inhibitor lapatinib exhibited potent drug synergy due to simultaneous blockade of MDR1 and ErbB receptor activity. Together, our findings suggest that concurrent blockade of MDR1 will likely be required in combination with PROTACs to achieve durable protein degradation and therapeutic response in cancer.

cancer biology↗